

| | | | |
|--------------------|---------------------|--------------------------|------------|
| Subject: | Xolair (omalizumab) | Publish Date: | 03/28/2022 |
| Document #: | ING-CC-0033 | Last Review Date: | 02/25/2022 |
| Status: | Revised | | |

Table of Contents

[Overview](#)
[Coding](#)
[References](#)
[Clinical criteria](#)
[Document history](#)

Overview

This document addresses the use of Xolair (omalizumab), an anti-IgE antibody approved by the Food and Drug Administration (FDA) to treat moderate to severe persistent asthma in individuals 6 years of age and older with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms inadequately controlled with inhaled corticosteroids. Xolair also has FDA approved indications as add-on maintenance treatment of nasal polyps in adults with inadequate response to nasal corticosteroids as well as treatment of chronic idiopathic urticaria in individuals age 12 and older who remain symptomatic despite H1 antihistamine treatment.

Asthma

FDA approval for Xolair for moderate to severe persistent asthma was based in part on the results of three randomized, double-blind, placebo-controlled, multi-center trials where the number of asthma exacerbations was the principal outcome. The trials enrolled subjects with moderate to severe persistent asthma, a positive skin test reaction to a perennial aeroallergen and a total IgE level greater than 30 IU/mL. The number of exacerbations was reduced in those receiving Xolair compared to the placebo group. However, individuals whose forced expiratory volume in 1 second (FEV₁) was greater than 80% predicted at enrollment did not experience a reduction in exacerbations.

The 2021 Global Initiative for Asthma (GINA) guidelines list Xolair as a treatment option in Step 5 of their asthma management algorithm. Add-on targeted biologic therapy should be considered for individuals with exacerbations or poor symptom control despite taking at least high-dose inhaled corticosteroid/long acting beta₂-agonists and who have allergic or eosinophilic biomarkers or need maintenance oral corticosteroids.

Comparative Doses for Inhaled Corticosteroids (Adults and Adolescents) (Wenzel 2021)

| Drug | Low Daily Dose | Medium Daily Dose | High Daily Dose |
|--|----------------------------|------------------------------|--------------------------------|
| Beclomethasone 40 or 80 mcg/actuation | 80-160 mcg | >160-320 mcg | >320-640 mcg |
| Budesonide 90 or 180 mcg/actuation | 180-360 mcg | >360-720 mcg | >720-1440 mcg |
| Ciclesonide 80 or 160 mcg/actuation | 160 mcg | 320 mcg | 640 mcg |
| Fluticasone propionate MDI: 44, 110 or 220 mcg/actuation DPI: 50, 100 or 250 mcg/dose | 176-220 mcg 100-250 mcg | >220-440 mcg >250-500 mcg | >440-1760 mcg >500-2000 mcg |
| Fluticasone furoate 50, 100 or 200 mcg/dose | 50 mcg | 100 mcg | 200 mcg |
| Mometasone MDI: 50, 100 or 200 mcg/actuation DPI: 110 or 220 mcg/actuation | 200 mcg 220 mcg | >200-400 mcg >220-440 mcg | >400-800 mcg >440-880 mcg |

DPI = dry powder inhaler, MDI = metered dose inhaler

Nasal Polyps

FDA approval for Xolair for nasal polyps was based on the results of two randomized, double-blind, placebo-controlled, multi-center trials where nasal polyp score (NPS) and nasal congestion score (NCS) were the principal outcome. The trials enrolled subjects with nasal polyps with inadequate response to nasal corticosteroids and a total IgE level greater than 30 IU/mL. Participants received Xolair or placebo in addition to background nasal mometasone therapy. The Xolair group had a statistically significant greater improvement at week 24 in NPS and NCS compared to the placebo group.

In 2014, the Joint Task Force on Practice Parameters (JTFPP) representing the American Academy of Allergy, Asthma & Immunology (AAAAI), the American College of Allergy, Asthma & Immunology (ACAAI) and the Joint Council of Allergy, Asthma & Immunology published a practice parameter on the diagnosis and management of rhinosinusitis. In 2015, the American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNS) published a clinical practice guideline on adult sinusitis. Both publications recommend confirming a clinical diagnosis of nasal polyps with imaging using anterior rhinoscopy, nasal endoscopy or computed tomography (CT). Intranasal corticosteroids are recommended for long-term treatment of nasal polyps. A short course of oral corticosteroids is included as a reasonable option to decrease polyp size and alleviate symptoms. Sinonasal surgery is another treatment option. The AAAAI/ACAAI guidance recommends consideration of Xolair for the treatment of nasal polyps when other medical and surgical options have failed.

Chronic Idiopathic Urticaria

Chronic idiopathic urticaria (CIU) is defined as itchy hives that last at least 6 weeks and have no apparent external trigger. The 2014 guidance from the Joint Task Force on Practice Parameters (JTFPP), representing the American Academy of Allergy, Asthma & Immunology (AAAAI), the American College of Allergy, Asthma & Immunology (ACAAI) and the Joint Council of Allergy, Asthma & Immunology, provides a step-based approach to the treatment of chronic urticaria. Xolair is included as an option in Step 4 of the algorithm when chronic urticaria has been refractory to treatment with potent antihistamines **and** leukotriene receptor antagonists.

Xolair carries a black box warning for anaphylaxis. Anaphylaxis has been reported after the first dose of Xolair but also beyond one year after beginning treatment. Xolair should be initiated in a healthcare setting and individuals should be closely observed for an appropriate period of time. Health care providers should be prepared to manage anaphylaxis and individuals should be instructed on anaphylaxis signs and symptoms and to seek immediate medical care should they occur. Selection of individuals for self-administration of Xolair should be based on criteria to mitigate risk from anaphylaxis.

Clinical Criteria

When a drug is being reviewed for coverage under a member's medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

Xolair (omalizumab)

Initial requests for Xolair (omalizumab) for moderate to severe persistent asthma may be if approved if the following criteria are met:

- I. Individual is 6 years of age or older; **AND**
- II. Individual has a diagnosis of moderate to severe persistent asthma; **AND**
- III. Documentation is provided that individual has had a 3 month trial and inadequate response or intolerance to combination controller therapy (high doses of inhaled corticosteroids plus long acting beta₂-agonists, leukotriene modifiers, long-acting muscarinic antagonists or oral corticosteroids) (GINA 2021); **AND**
- IV. Individual has a positive skin test or in vitro reactivity to a perennial aeroallergen; **AND**
- V. Individual has a pretreatment forced expiratory volume in one second (FEV₁) less than 80% predicted; **AND**
- VI. Documentation is provided that individual has a serum Immunoglobulin E (IgE) level equal to or greater than 30 IU/mL.

Continuation requests for Xolair (omalizumab) for moderate to severe persistent asthma may be if approved if the following criteria are met:

- I. Treatment with Xolair has resulted in clinical improvement as confirmed by one or more of the following:
 - A. Decreased utilization of rescue medications; **OR**
 - B. Decreased frequency of exacerbations (defined as worsening of asthma that requires increase in inhaled corticosteroid dose or treatment with systemic corticosteroids); **OR**
 - C. Increase in percent predicted FEV₁ from pretreatment baseline; **OR**
 - D. Reduction in reported asthma-related symptoms, such as but not limited to wheezing, shortness of breath, coughing, fatigue, sleep disturbance, or asthmatic symptoms upon awakening.

Initial requests for Xolair (omalizumab) for nasal polyps may be if approved if the following criteria are met:

- I. Individual is 18 years of age or older; **AND**
- II. Individual has a diagnosis of nasal polyps; **AND**
- III. Documentation is provided that presence of bilateral nasal polyps have been confirmed by one of the following (AAO-HNS 2015):
 - A. Anterior rhinoscopy; **OR**
 - B. Nasal endoscopy; **OR**
 - C. Computed tomography (CT); **AND**
- IV. Individual has had a trial and inadequate response to maintenance intranasal corticosteroids; **AND**
- V. Individual is refractory to or is ineligible or intolerant to the following (AAAAI/ACAAI 2014):
 - A. Systemic corticosteroids; **OR**
 - B. Sinonasal surgery; **AND**
- VI. Individual is requesting Xolair as add-on therapy to maintenance intranasal corticosteroids; **AND**
- VII. Documentation is provided that individual has a serum Immunoglobulin E (IgE) level greater than or equal to 30 IU/mL.

Continuation requests for Xolair (omalizumab) for nasal polyps may be if approved if the following criterion is met:

- I. Treatment with Xolair has resulted in confirmed clinically significant improvement in clinical signs and symptoms of disease (including but not limited to improvement in nasal congestion or reduced nasal polyp size; **AND**
- II. Individual continues to use Xolair in combination with maintenance intranasal corticosteroids.

Initial requests for Xolair (omalizumab) for chronic idiopathic urticaria (CIU) may be approved if the following criteria are met:

- I. Individual is 12 years of age or older; **AND**
- II. Individual has a diagnosis of chronic idiopathic urticaria (CIU); **AND**
- III. Individual has had a trial and inadequate response or intolerance to H₁ antihistamines and H₂ antihistamines (AAAAI/ACAAI 2014); **AND**
- IV. Documentation is provided that individual has had a trial and inadequate response or intolerance to leukotriene receptor antagonists (AAAAI/ACAAI 2014).

Continuation requests for Xolair (omalizumab) for chronic idiopathic urticaria (CIU) may be approved if the following criterion is met:

- I. Treatment with Xolair has resulted in confirmed clinically significant improvement or stabilization in clinical signs and symptoms of disease (including but not limited to itch severity and hive count).

Xolair (omalizumab) may not be approved for the following;

- I. In combination with Cinqair, Dupixent, Fasentra, Nucala, or Tezspire; **OR**
- II. May not be approved with the above criteria are not met and for all other indications.

Approval Duration

Initial Requests: 6 months

Continuation Requests: 12 months

Quantity Limits

Xolair (omalizumab) Quantity Limit

| Drug | Limit |
|--|--|
| Xolair (omalizumab) 150 mg vial, 75 mg and 150 mg syringes | Asthma: 375 mg as frequently as every 2 weeks |
| | Nasal Polyps: 600 mg as frequently as every 2 weeks |
| | Chronic Idiopathic Urticaria: 300 mg every 4 weeks |

Coding

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement

policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

HCPCS

J2357 Injection, omalizumab, 5 mg [Xolair]

ICD-10 Diagnosis

J33.0-J33.9 Nasal polyp

J44.0-J44.9 Other chronic obstructive pulmonary disease [with asthma]

J45.20-J45.998 Asthma

L50.0-L50.9 Urticaria

Document History

Revised: 2/25/2022

Document History:

- 2/25/2022 – Annual Review: Align nasal polyp continuation criteria with criteria for other biologics. Add may not approve criteria for use with other biologics. Update guideline references. Coding Reviewed: No changes.
- 08/01/2021 – Administrative update to add documentation.
- 02/19/2021 – Annual Review: Update requirements for trial of combination therapy in asthma criteria. Add criteria for nasal polyps. Update quantity limit based on indication. Update references. Coding Reviewed: Added ICD-10-CM J33.0-J33.9.
- 02/21/2020 – Annual Review: Update prior trial requirement for asthma from medium-to-high to high dose ICS. Add continuation criteria for chronic idiopathic urticaria. Clarify approval duration. Wording and formatting changes. Update references. Coding Reviewed: No changes.
- 09/23/2019 – Administrative update to add drug specific quantity limit.
- 02/22/2019 – Annual Review: Update Xolair criteria to align prior trial requirements with other agents for severe asthma. Wording and formatting updates for consistency with other agents for severe asthma.
- 08/17/2018 – Selected Review: Initial P&T review of Xolair clinical criteria. Wording updates to prior trial requirements and addition of references. Update continuation criteria by removing requirement to meet initiation criteria.

References

1. Bernstein JA, Lang DM, Khan DA, et al. Joint Task Force on Practice Parameters (JTFPP), representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council of Allergy, Asthma & Immunology. Practice parameter: the diagnosis and management of acute and chronic urticaria: 2014 update. *J Allerg Clin Immunol*. 2014; 133(5):1270-1277.
2. Chung KF, Wenzel SE, Brozek JL, et al. International European Respiratory Society/American Thoracic Society (ERS/ATS) guidelines on definition, evaluation and treatment of severe asthma. *Eur Respir J*. 2014; 43(2):343-373.
3. Cloutier MM, Baptist AP, Blake KV, et al. 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program (NAEPP) Coordinating Committee Expert Panel Working Group. *J Allergy Clin Immunol*. 2020 Dec;146(6):1217-1270.
4. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: January 12, 2022.
5. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
6. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2021. Available from: <http://ginasthma.org/gina-reports/>. Accessed on: January 14, 2022.
7. Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. *Eur Respir J*. 2020 Jan 2;55(1):1900588.
8. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2022; Updated periodically.
9. National Asthma Education and Prevention Program (NAEPP). Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. NIH Publication Number 08-5846. Updated: August 5, 2008. Available at: <http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm>. Accessed: January 14, 2022.
10. Peters AT, Spector S, Hsu J, et al. Joint Task Force on Practice Parameters (JTFPP), representing the American Academy of Allergy, Asthma & Immunology (AAAAI), the American College of Allergy, Asthma & Immunology (ACAAI) and the Joint Council of Allergy, Asthma & Immunology. Diagnosis and management of rhinosinusitis: a practice parameter update. *American College of Allergy, Asthma & Immunology*. 2014;113:347-385.

11. Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et.al. American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNS). Clinical Practice Guideline (Update): Adult Sinusitis. *Otolaryngology-Head and Neck Surgery*. 2015;152(2S)SI-S39.
12. Wenzel S. Treatment of severe asthma in adolescents and adults. Last updated: December 3, 2021. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. Accessed: January 14, 2022.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association